세계의 부트리시란(Vutrisiran) 시장 보고서(2025년)

Vutrisiran Global Market Report 2025

US $ 4,490 ￦ 6,301,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,108,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,914,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

2029년에는 12.4%의 연평균 복합 성장률(CAGR)로, 10억 8,000만 달러로 성장할 것으로 예측됩니다. 연구개발 투자 증가, 맞춤형 의료의 중시의 고조, 질환에 대한 인식 제고에 따른 것입니다.

연구개발에 대한 투자 증가는 향후 몇 년간의 부트리시란 시장의 성장을 가속할 것으로 예측됩니다. 의료 및 의약품 수요 증가, 지속가능성에 대한 노력, 환경에 대한 우려에 기인하고 있습니다. RNA 간섭(RNAi) 기술의 진보에 의해 약제의 정밀도가 향상되어, 부작용이 최소한으로 억제되어, 환자에의 보급이 진행됩니다. 2023년 12월 룩셈부르크에 본사를 둔 유럽 연합 통계청인 유로스타트(Eurostat)는 2022년에 유럽 연합의 연구 개발 지출이 3,520억 유로(3,844억 2,000만 달러)에 달하고 전년의 3,310억 유로(3,614억 8,000만 달러)로부터 6.34% 증가했다고 보고했습니다.

부트리시란 시장에서 사업을 전개하는 기업은 유전성 트랜스사이레틴 개재성(hATTR) 아밀로이드증을 관리하기 위해 보다 편리하고 투여 빈도가 적은 옵션을 제공하는 피하 RNAi 치료제 등의 혁신적인 치료법의 개발에 주력하고 있습니다. 이 방법은 장기간에 걸쳐 약물 농도가 일정하게 유지되기 때문에 유전성 트랜스사이레틴 개입(hATTR) 아밀로이드증과 관련된 다발성 신경병증의 치료에서 환자의 편의성과 어드히어런스가 향상됩니다. 바이오의약품회사인 알나이람 퍼머슈티컬즈사는 부트리시란(AMVUTTRA)이 유전성 트랜스사이레틴을 통한(hATTR)아밀로이드증의 성인에서 다발성 신경장애의 치료제로서 식품의약국(FDA)으로부터 승인을 취득했다고 발표했습니다. 이 약물은 신경병증 증상을 대폭 완화하고 질병의 진행을 지연시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 부트리시란 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 부트리시란 시장 : 성장률 분석
• 세계의 부트리시란 시장 실적 : 규모와 성장, 2019-2024
• 세계의 부트리시란 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계의 부트리시란 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 부트리시란 시장 : 약제 클래스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 안티센스 올리고뉴클레오티드
• 핵산
• 뉴클레오티드
• 뉴클레오시드
• 기타 약물 클래스
• 세계의 부트리시란 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 오랄
• 주사제
• 피하
• 세계의 부트리시란 시장 : 환자 인구 통계별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 소아과
• 성인용
• 고령자
• 세계의 부트리시란 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타 유통 채널
• 세계의 부트리시란 시장 : 안티센스 올리고뉴클레오티드유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 단일 가닥 안티센스 올리고뉴클레오티드
• 이중 가닥 안티센스 올리고뉴클레오티드
• 세계의 부트리시란 시장 : 핵산유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• DNA 기반 핵산
• RNA 기반 핵산
• 세계의 부트리시란 시장 : 뉴클레오티드유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 푸딩뉴클레오티드
• 피리미딘뉴클레오티드
• 세계의 부트리시란 시장 : 뉴클레오시드유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 푸딩 뉴클레오시드
• 피리미딘 뉴클레오시드
• 세계의 부트리시란 시장 : 기타 약물 클래스 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 펩티드계 의약품
• 단백질 세라퓨틱스

제7장 지역별/국가별 분석

• 세계의 부트리시란 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 부트리시란 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 부트리시란 시장 : 경쟁 구도
• 부트리시란 시장 : 기업 프로파일
  • Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 세계 시장 경쟁 벤치마킹과 대시보드

제32장 주요 인수합병(M&A)

제33장 최근 시장 동향

제34장 시장의 잠재력이 높은 국가, 부문, 전략

• 부트리시란 시장 2029 : 새로운 기회를 제공하는 국가
• 부트리시란 시장 2029 : 새로운 기회를 제공하는 부문
• 부트리시란 시장 2029 : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제35장 부록

SHW

영문 목차

영문목차

Vutrisiran is a small interfering RNA (siRNA) therapy used to treat hereditary transthyretin-mediated (hATTR) amyloidosis. It works by silencing the transthyretin (TTR) gene, reducing abnormal TTR protein deposits responsible for polyneuropathy and organ damage. Vutrisiran helps slow disease progression while improving neurological function, mobility, and overall quality of life, offering the benefit of a longer dosing interval.

The primary drug classes for vutrisiran include antisense oligonucleotides, nucleic acids, nucleotides, nucleosides, and others. Antisense oligonucleotides (ASOs) are synthetic short DNA or RNA molecules designed to target specific mRNA sequences and regulate gene expression. Vutrisiran is administered through various routes, including oral, injectable, and subcutaneous, and is suitable for different patient demographics, including pediatric, adult, and geriatric populations. It is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

The vutrisiran market research report is one of a series of new reports from The Business Research Company that provides vutrisiran market statistics, including the vutrisiran industry global market size, regional shares, competitors with the vutrisiran market share, detailed vutrisiran market segments, market trends, and opportunities, and any further data you may need to thrive in the vutrisiran industry. This vutrisiran market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vutrisiran market size has grown rapidly in recent years. It will grow from $0.60 billion in 2024 to $0.68 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be attributed to increasing awareness of hereditary transthyretin amyloidosis, a rise in clinical trials, growing healthcare spending, a higher patient preference for non-invasive administration methods, and an increasing prevalence of genetic disorders.

The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The projected growth in the forecast period is driven by expanding healthcare availability, a rising prevalence of chronic diseases, increased investment in research and development, a growing emphasis on personalized medicine, and greater awareness of the disease. Key trends include advancements in combination therapy, the adoption of targeted therapy, progress in personalized medicine, the development of digital health technologies, and innovations in biotechnology.

The increasing investment in research and development is expected to drive the growth of the vutrisiran market in the coming years. Research and development involve innovating and enhancing products, services, or processes through systematic investigation and experimentation. The rise in R&D investment is attributed to government initiatives and funding, increasing healthcare and pharmaceutical demands, sustainability efforts, and environmental concerns. Funding for research and development enables pharmaceutical companies to conduct clinical trials, demonstrating the drug's long-term efficacy and safety, leading to wider regulatory approvals. Additionally, advancements in RNA interference (RNAi) technology enhance the drug's precision, minimizing side effects and increasing patient adoption. For example, in December 2023, Eurostat, a Luxembourg-based statistical office of the European Union, reported that the European Union's research and development expenditure reached €352 billion ($384.42 billion) in 2022, reflecting a 6.34% increase from €331 billion ($361.48 billion) in the previous year. As a result, rising investments in research and development are fueling the expansion of the vutrisiran market.

Companies operating in the vutrisiran market are focusing on developing innovative treatments, such as subcutaneous RNAi therapeutics, to offer more convenient and less frequent dosing options for managing hereditary transthyretin-mediated (hATTR) amyloidosis. These therapeutics utilize RNA interference technology and are administered through injections under the skin, ensuring sustained drug release. This approach maintains consistent drug levels over time, enhancing patient convenience and adherence in treating polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. For example, in June 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, announced that vutrisiran (AMVUTTRA) received approval from the Food and Drug Administration (FDA) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. The drug significantly alleviates neuropathy symptoms and slows disease progression. In the HELIOS-A Phase 3 study, more than 50% of patients showed a reversal or halt in disease manifestations. AMVUTTRA has demonstrated a favorable safety profile, with no drug-related discontinuations or fatalities, and features a dosing regimen that may enhance patient compliance.

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, collaborated with Alnylam Pharmaceuticals Inc. to extend the commercialization of RNAi therapeutics. This partnership seeks to increase global availability of Alnylam's innovative RNAi treatments, particularly for patients with rare diseases, by leveraging Medison's integrated commercialization platform across multiple regions, including LATAM, APAC, and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures vutrisiran.

The key player in the vutrisiran market is Alnylam Pharmaceuticals Inc.

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vutrisiran report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vutrisiran market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vutrisiran market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vutrisiran Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vutrisiran market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vutrisiran ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vutrisiran market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antisense Oligonucleotide; Nucleic Acids; Nucleotide; Nucleoside; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable; Subcutaneous
• 3) By Patient Demographics: Pediatric; Adult; Geriatric
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides; Double-Stranded Antisense Oligonucleotides
• 2) By Nucleic Acids: DNA-based Nucleic Acids; RNA-based Nucleic Acids
• 3) By Nucleotide: Purine Nucleotides; Pyrimidine Nucleotides
• 4) By Nucleoside: Purine Nucleosides; Pyrimidine Nucleosides
• 5) By Other Drug Classes: Peptide-Based Drugs; Protein Therapeutics
• Companies Mentioned: Alnylam Pharmaceuticals Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vutrisiran Market Characteristics

3. Vutrisiran Market Trends And Strategies

4. Vutrisiran Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vutrisiran Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vutrisiran PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vutrisiran Market Growth Rate Analysis
• 5.4. Global Vutrisiran Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vutrisiran Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vutrisiran Total Addressable Market (TAM)

6. Vutrisiran Market Segmentation

• 6.1. Global Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antisense Oligonucleotide
• Nucleic Acids
• Nucleotide
• Nucleoside
• Other Drug Classes
• 6.2. Global Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Subcutaneous
• 6.3. Global Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric
• 6.4. Global Vutrisiran Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Vutrisiran Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Stranded Antisense Oligonucleotides
• Double-Stranded Antisense Oligonucleotides
• 6.6. Global Vutrisiran Market, Sub-Segmentation Of Nucleic Acids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA-based Nucleic Acids
• RNA-based Nucleic Acids
• 6.7. Global Vutrisiran Market, Sub-Segmentation Of Nucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Purine Nucleotides
• Pyrimidine Nucleotides
• 6.8. Global Vutrisiran Market, Sub-Segmentation Of Nucleoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Purine Nucleosides
• Pyrimidine Nucleosides
• 6.9. Global Vutrisiran Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptide-Based Drugs
• Protein Therapeutics

7. Vutrisiran Market Regional And Country Analysis

• 7.1. Global Vutrisiran Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vutrisiran Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vutrisiran Market

• 8.1. Asia-Pacific Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vutrisiran Market

• 9.1. China Vutrisiran Market Overview
• 9.2. China Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vutrisiran Market

• 10.1. India Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vutrisiran Market

• 11.1. Japan Vutrisiran Market Overview
• 11.2. Japan Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vutrisiran Market

• 12.1. Australia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vutrisiran Market

• 13.1. Indonesia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vutrisiran Market

• 14.1. South Korea Vutrisiran Market Overview
• 14.2. South Korea Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vutrisiran Market

• 15.1. Western Europe Vutrisiran Market Overview
• 15.2. Western Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vutrisiran Market

• 16.1. UK Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vutrisiran Market

• 17.1. Germany Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vutrisiran Market

• 18.1. France Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vutrisiran Market

• 19.1. Italy Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vutrisiran Market

• 20.1. Spain Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vutrisiran Market

• 21.1. Eastern Europe Vutrisiran Market Overview
• 21.2. Eastern Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vutrisiran Market

• 22.1. Russia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vutrisiran Market

• 23.1. North America Vutrisiran Market Overview
• 23.2. North America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vutrisiran Market

• 24.1. USA Vutrisiran Market Overview
• 24.2. USA Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vutrisiran Market

• 25.1. Canada Vutrisiran Market Overview
• 25.2. Canada Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vutrisiran Market

• 26.1. South America Vutrisiran Market Overview
• 26.2. South America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vutrisiran Market

• 27.1. Brazil Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vutrisiran Market

• 28.1. Middle East Vutrisiran Market Overview
• 28.2. Middle East Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vutrisiran Market

• 29.1. Africa Vutrisiran Market Overview
• 29.2. Africa Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vutrisiran Market Competitive Landscape And Company Profiles

• 30.1. Vutrisiran Market Competitive Landscape
• 30.2. Vutrisiran Market Company Profiles
  • 30.2.1. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Global Vutrisiran Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Vutrisiran Market

33. Recent Developments In The Vutrisiran Market

34. Vutrisiran Market High Potential Countries, Segments and Strategies

• 34.1 Vutrisiran Market In 2029 - Countries Offering Most New Opportunities
• 34.2 Vutrisiran Market In 2029 - Segments Offering Most New Opportunities
• 34.3 Vutrisiran Market In 2029 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer